UPMC PASSAVANT
1. Target Overview & Investment Thesis
UPMC PASSAVANT is a 354-bed suburban community hospital in ALLEGHENY, PA with $394.5M in net patient revenue and a -23.2% operating margin. The hospital serves a payer mix of 22.2% Medicare, 0.7% Medicaid, and 77.2% commercial.
Thesis: Undervalued. Our ML models identify $29.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -23.2% to -15.8% (+736bps).
| Net Revenue HCRIS | $394.5M |
| Current EBITDA COMPUTED | $-91.4M |
| Operating Margin COMPUTED | -23.2% |
| Occupancy HCRIS | 56.2% |
| Revenue / Bed COMPUTED | $1.1M |
| Net-to-Gross HCRIS | 14.2% |
| Distress Probability ML | 44.8% |
2. Market Context & Competitive Position
PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -23.2% places it below the state median. Among 63 size-comparable peers (177-708 beds), the median margin is -7.5%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (177-708), prioritizing same-state peers. 63 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| UPMC PASSAVANT (Target) | PA | 354 | $394.5M | -23.2% |
| ST. LUKES HOSPITAL | PA | 633 | $8.94B | 87.9% |
| THE CHILDRENS HOSPITAL OF PHIL | PA | 667 | $2.70B | -26.8% |
| MILTON S. HERSHEY MEDICAL CENT | PA | 616 | $2.08B | -2.8% |
| GEISINGER MEDICAL CENTER | PA | 525 | $1.58B | 4.1% |
| YORK HOSPITAL | PA | 533 | $1.47B | 9.7% |
| LANCASTER GENERAL HOSPITAL | PA | 620 | $1.33B | -2.6% |
| UPMC PINNACLE HOSPITALS | PA | 561 | $1.29B | 8.9% |
| READING HOSPITAL AND MEDICAL C | PA | 561 | $1.15B | 6.1% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $29.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $8.3M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $7.9M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $7.8M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $4.8M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $252K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-91.4M |
| + RCM Uplift | +$29.0M |
| Pro Forma EBITDA | $-62.4M |
| Current Margin | -23.2% |
| Pro Forma Margin | -15.8% |
| WC Released (1x) | $15.1M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-140.6M | $-312.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-140.6M | $-389.4M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-126.5M | $-339.2M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-126.5M | $-407.4M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-154.7M | $-412.0M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-154.7M | $-503.4M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 63 hospitals with 177-708 beds
- Same-state prioritization (n=64)
- Comp margins: P25=-17.3% / P50=-7.5% / P75=-0.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.